Literature DB >> 7872135

Parkinson's disease: drug-induced psychiatric states.

S A Factor1, E S Molho, G D Podskalny, D Brown.   

Abstract

Drug-induced psychiatric states occur frequently in PD. In the prelevodopa era, depression and other psychiatric disorders were described in PD, but in untreated patients psychosis was rare. Since the development of levodopa and other pharmacological treatments for PD, however, psychotic symptoms have become much more common (10-50%). In some individuals these problems can be more disabling than the motor features of PD and, as a result, pose a serious threat to the patient's ability to maintain independence. The drug-induced psychoses consist of several distinct psychiatric syndromes that can be divided broadly into those occurring on a background of a clear sensorium and those which are accompanied by confusion and clouding of consciousness. Benign organic hallucinosis is the most common of these syndromes (30%). It usually occurs on a background of a clear sensorium and may not be a particularly troublesome problem if the patient is able to retain insight into the nature of these symptoms. More disabling syndromes usually include delusional thinking that is frequently paranoid, confusion and even frank delirium. Although all these psychotic syndromes can occur in isolation, there is a tendency for mild symptoms to progress to more disabling ones if adequate and timely treatment is not instituted. Abnormal dreaming and sleep disruption often precede these difficulties by weeks to months and may provide an important early clue to their onset. The mechanisms responsible for drug-induced psychotic symptoms in PD are unknown, but dopaminergic (especially mesolimbic) and serotoninergic systems are likely to be involved. The treatment of the drug-induced psychoses in PD should be undertaken in a stepwise manner. A detailed discussion of this approach, including the use of anti-PD medication adjustment, clozapine, and other medications (neuroleptic and nonneuroleptic) and ECT is provided (see Fig. 1). Although drug-induced psychoses are the most important of the drug-induced psychiatric states, mania, anxiety, and hypersexuality may also occur. Depression is also common in PD, but it is unlikely to occur as a side effect of antiparkinsonian medications.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7872135

Source DB:  PubMed          Journal:  Adv Neurol        ISSN: 0091-3952


  33 in total

Review 1.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

2.  Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors:  P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

3.  Hallucinosis in idiopathic Parkinson's disease.

Authors:  J M Graham; R A Grünewald; H J Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 4.  Cabergoline-induced manic episode: case report.

Authors:  Rabia Nazik Yüksel; Zeynep Elyas Kaya; Nesrin Dilbaz; Merve Cingi Yirün
Journal:  Ther Adv Psychopharmacol       Date:  2016-01-21

5.  The temporal lobe is a target of output from the basal ganglia.

Authors:  F A Middleton; P L Strick
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

6.  Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinson's disease.

Authors:  Krista Specketer; Cyrus P Zabetian; Karen L Edwards; Lu Tian; Joseph F Quinn; Amie L Peterson-Hiller; Kathryn A Chung; Shu-Ching Hu; Thomas J Montine; Brenna A Cholerton
Journal:  J Clin Exp Neuropsychol       Date:  2019-06-10       Impact factor: 2.475

7.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

Review 8.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

10.  Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study.

Authors:  Daniel Ecker; Alexander Unrath; Jan Kassubek; Michael Sabolek
Journal:  BMC Neurol       Date:  2009-06-10       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.